EFTA02571881.pdf

From: Masha Drokova < Sent: Friday, November 3, 2017 7:19 AM To: Jeffrey E. Subject: Re: what is investor type btw? w=at is one main quality for investor? On Nov 2, 2017, at 9:53 PM, jeffrey E. <jeevacation@gmail.com <mailto:jeevacation@g=ail.com» wrote: He is not an investor type . He is s p=rtner at a firm but used to be at Microsoft. Just use him for advice<=div> On Thu, Nov 2, 2017 at 11:13 PM Mas=a Drokova > wrote: =div> Thank you for the comprehensive feedback Steven. =div> <=iv>For me the main val=e is that the system is an order of magnitude cheaper than existing technol=gies, premised on leveraging data to help users see what daily elements are=affecting their blood sugar, and predicting dangerous highs and lows before=they happen so they can take actions beforehand. To date, their beta app has lowered b=ood sugar averages in over 55% of users 2x better than the world's most pre=cribed diabetes drug, Metformin. Which means that with the help of the date=diabetes would need to use less drugs. However I'd agree on complexity of regulations a=d saturation on the market. I run Day=One Ventures fund and based in San Francisco. I'd be happy to connect in pe=son sometime to learn about about your experience and tell about our invest=ents and opportunities I see. O= Nov 2, 2017, at 3:24 PM, Steven Sinofsky >> wrote: =blockquote type="cite"> Greetings Masha, I apologize for the delay. I was at some events in in UK w=ere I did not have connectivity. I have worked on a=related portfolio company so I will have to be a bit abstract on the specif=cs of this opportunity. So please excuse these brief thoughts. Also, t=e only information I had was what was provided in your mail which was limit=d relative to any detailed analysis. In general t=e challenge with glucose measurement is the finger prick. Any device that r=lies on this will only be marginally better than any other device, whether o= not there is software or a slightly more convenient EFTA_R1_01741122 EFTA02571881 measuring device. This=is a statement about the inconvenience of a prick (and long term challenges= but also the medical challenges on relying on that point in time. * My sense is that going down the path of an innovation, that still has a p=ick, but requires a level of FDA approval is a difficult one to approach.</=iv> • This is a very crowded space. There are a lot of apps, a lot of m=asuring devices, a lot of mixtures of app and measuring devices. It is very=difficult to avoid appearing as a commodity to consumers. • While=l understand there is potential to see innovation using novel approaches to=analysis of data, it is not clear to me how much better the approach can be=for an individual with data. * The real opportunity I might see i= around measuring glucose or some related telemetry to assist in compliance=that is outside the scope of a finger prick and measuring glucose directly.=It seems like we should have some other data point upon which to apply mach=ne learning. I hope this helps...any friend of JE i= a friend of mine. On Nov 1, 2017, at 4:43 PM, Masha Drokova &=1 » wrote: </=iv> Thank you Jeffrey. Steve, great meeting you. Would a=preciate your feedback On Nov 1, 2017, at 9:31 AM, jeff=ey E. <jeevac=tion@gmail.com <mailto:jeevacation@gmail.com» wrote: <=iv>steve can you give some guidance On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova <=pan>< > wrote: I'm looking to invest at the company doing Al-based glucose monitoring s=stem for people with diabetes. We made tech evaluation, talked to a f=w experts and more a question about the market and regulations. Likely no, &=bsp;because it's complex area, but still thinking of them. May be someone in=your network who knows this area and can advise on this kind of tech? =/span> =font face="Roboto-Regular">Center Health Deck: Pros — Existing glucometers from big companies are very old-fas=ioned and outdated, those companies make their revenue from overpriced stri=s — Direct competitors, such as iHealth an= Dario have negative customer reviews and minor — Uses FDA-app=oved circuits to get the approval in an automated manner 2 EFTA_R1_01741123 EFTA02571882  Cons — Enormous pressure both from t=e industry players and companies such as Apple and Google that try to devel=p non-invasive glucose monitoring that will wipe out test strip products — Hardware startup without a product to sell yet, finaliz=ng the development — Young team please note confidential, may be a=torney-client privileged, may constitute inside information, and is inte=ded only for the use of the addressee. It is the property of JEE U=authorized use, disclosure or copying of this communication or any part t=ereof is strictly prohibited and may be unlawful. If you have received t=is communication in error, please notify us immediately by return e-m=il or by e-mail to jeevacation@gmail.com <mailto:jeevacation@gmail.com> , and destroy this communication and all copi=s thereof, including all attachments. copyright -all rights reserved =/div> =/div> &nb=p; please note The information contained in this commun=cation is confidential, may be attorney-client privileged, may consti=ute inside information, and is intended only for the use of the addresse=. It is the property of JEE Unauthorized use, disclosure or copying o= this communication or any part thereof is strictly prohibited and ma= be unlawful. If you have received this communication in error, please n=tify us immediately by return e-mail or by e-mail to jeevacation@gmail.com <mailto:j=evacation@gmail.com> , and de=troy this communication and all copies thereof, including all attachment=. copyright -all rights reserved 3 EFTA_R1_01741124 EFTA02571883